317 related articles for article (PubMed ID: 10072072)
1. Cathepsin S required for normal MHC class II peptide loading and germinal center development.
Shi GP; Villadangos JA; Dranoff G; Small C; Gu L; Haley KJ; Riese R; Ploegh HL; Chapman HA
Immunity; 1999 Feb; 10(2):197-206. PubMed ID: 10072072
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin S activity regulates antigen presentation and immunity.
Riese RJ; Mitchell RN; Villadangos JA; Shi GP; Palmer JT; Karp ER; De Sanctis GT; Ploegh HL; Chapman HA
J Clin Invest; 1998 Jun; 101(11):2351-63. PubMed ID: 9616206
[TBL] [Abstract][Full Text] [Related]
3. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation.
Maurer D; Fiebiger E; Reininger B; Ebner C; Petzelbauer P; Shi GP; Chapman HA; Stingl G
J Immunol; 1998 Sep; 161(6):2731-9. PubMed ID: 9743330
[TBL] [Abstract][Full Text] [Related]
4. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages.
Shi GP; Bryant RA; Riese R; Verhelst S; Driessen C; Li Z; Bromme D; Ploegh HL; Chapman HA
J Exp Med; 2000 Apr; 191(7):1177-86. PubMed ID: 10748235
[TBL] [Abstract][Full Text] [Related]
5. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice.
Nakagawa TY; Brissette WH; Lira PD; Griffiths RJ; Petrushova N; Stock J; McNeish JD; Eastman SE; Howard ED; Clarke SR; Rosloniec EF; Elliott EA; Rudensky AY
Immunity; 1999 Feb; 10(2):207-17. PubMed ID: 10072073
[TBL] [Abstract][Full Text] [Related]
6. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading.
Riese RJ; Wolf PR; Brömme D; Natkin LR; Villadangos JA; Ploegh HL; Chapman HA
Immunity; 1996 Apr; 4(4):357-66. PubMed ID: 8612130
[TBL] [Abstract][Full Text] [Related]
7. Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in vivo.
Beers C; Burich A; Kleijmeer MJ; Griffith JM; Wong P; Rudensky AY
J Immunol; 2005 Feb; 174(3):1205-12. PubMed ID: 15661874
[TBL] [Abstract][Full Text] [Related]
8. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism.
Villadangos JA; Riese RJ; Peters C; Chapman HA; Ploegh HL
J Exp Med; 1997 Aug; 186(4):549-60. PubMed ID: 9254653
[TBL] [Abstract][Full Text] [Related]
9. The protease inhibitor cystatin C is differentially expressed among dendritic cell populations, but does not control antigen presentation.
El-Sukkari D; Wilson NS; Hakansson K; Steptoe RJ; Grubb A; Shortman K; Villadangos JA
J Immunol; 2003 Nov; 171(10):5003-11. PubMed ID: 14607896
[TBL] [Abstract][Full Text] [Related]
10. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation.
Hsieh CS; deRoos P; Honey K; Beers C; Rudensky AY
J Immunol; 2002 Mar; 168(6):2618-25. PubMed ID: 11884425
[TBL] [Abstract][Full Text] [Related]
11. Asparagine endopeptidase is not essential for class II MHC antigen presentation but is required for processing of cathepsin L in mice.
Maehr R; Hang HC; Mintern JD; Kim YM; Cuvillier A; Nishimura M; Yamada K; Shirahama-Noda K; Hara-Nishimura I; Ploegh HL
J Immunol; 2005 Jun; 174(11):7066-74. PubMed ID: 15905550
[TBL] [Abstract][Full Text] [Related]
12. Proteases involved in MHC class II antigen presentation.
Villadangos JA; Bryant RA; Deussing J; Driessen C; Lennon-Duménil AM; Riese RJ; Roth W; Saftig P; Shi GP; Chapman HA; Peters C; Ploegh HL
Immunol Rev; 1999 Dec; 172():109-20. PubMed ID: 10631941
[TBL] [Abstract][Full Text] [Related]
13. Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies.
Wiendl H; Lautwein A; Mitsdörffer M; Krause S; Erfurth S; Wienhold W; Morgalla M; Weber E; Overkleeft HS; Lochmüller H; Melms A; Tolosa E; Driessen C
J Neuroimmunol; 2003 May; 138(1-2):132-43. PubMed ID: 12742663
[TBL] [Abstract][Full Text] [Related]
14. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells.
Pierre P; Mellman I
Cell; 1998 Jun; 93(7):1135-45. PubMed ID: 9657147
[TBL] [Abstract][Full Text] [Related]
15. T cell-depleted splenocytes from mice pre-immunized with neuroantigen in incomplete Freund's adjuvant involved in protection from experimental autoimmune encephalomyelitis.
Zheng H; Zhang H; Liu F; Qi Y; Jiang H
Immunol Lett; 2014; 157(1-2):38-44. PubMed ID: 24220208
[TBL] [Abstract][Full Text] [Related]
16. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
17. Regulation of CD1 function and NK1.1(+) T cell selection and maturation by cathepsin S.
Riese RJ; Shi GP; Villadangos J; Stetson D; Driessen C; Lennon-Dumenil AM; Chu CL; Naumov Y; Behar SM; Ploegh H; Locksley R; Chapman HA
Immunity; 2001 Dec; 15(6):909-19. PubMed ID: 11754813
[TBL] [Abstract][Full Text] [Related]
18. Invariant chain processing is independent of cathepsin variation between primary human B cells/dendritic cells and B-lymphoblastoid cells.
Reich M; Zou F; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
Cell Immunol; 2011; 269(2):96-103. PubMed ID: 21543057
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of invariant chain processing, antigen-induced proliferative responses, and the development of collagen-induced arthritis and experimental autoimmune encephalomyelitis by a small molecule cysteine protease inhibitor.
Podolin PL; Bolognese BJ; Carpenter DC; Davis TG; Johanson RA; Fox JH; Long E; Dong X; Marquis RW; Locastro SM; Terfloth GJ; Kurali E; Peterson JJ; Smith BR; McQueney MS; Yamashita DS; Capper-Spudich EA
J Immunol; 2008 Jun; 180(12):7989-8003. PubMed ID: 18523262
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of major histocompatibility complex class II compartments during B cell receptor-mediated cell activation.
Lankar D; Vincent-Schneider H; Briken V; Yokozeki T; Raposo G; Bonnerot C
J Exp Med; 2002 Feb; 195(4):461-72. PubMed ID: 11854359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]